Management of Low Bone Mineral Density in Premenopausal Women

Journal of Obstetrics and Gynaecology Canada

Volumn 27, Issue 4, 2005, Pages 345-349

  Khan, Aliya ^a  

^a MCMASTER UNIVERSITY   (Canada)

Author keywords

Low bone density; Osteoporosis; Premenopausal women; Therapy

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; GLUCOCORTICOID; MEDROXYPROGESTERONE ACETATE; ORAL CONTRACEPTIVE AGENT;

ARTICLE; BODY HEIGHT; BODY WEIGHT; BONE DENSITY; BONE MASS; CALCIUM INTAKE; ENVIRONMENTAL FACTOR; ESTROGEN THERAPY; FRAGILITY FRACTURE; HUMAN; LIFESTYLE MODIFICATION; OSTEOLYSIS; OSTEOPOROSIS; OVARY INSUFFICIENCY; POPULATION RISK; PRACTICE GUIDELINE; PREMENOPAUSE; RANDOMIZED CONTROLLED TRIAL (TOPIC); ADULT; AGE; BONE DISEASE; CLINICAL TRIAL; FEMALE; GENERAL ASPECTS OF DISEASE; META ANALYSIS; OVULATION; PATHOLOGIC FRACTURE; PHYSIOLOGY; RISK FACTOR;

ADULT; AGE FACTORS; BODY HEIGHT; BONE DENSITY; BONE DISEASES; BONE RESORPTION; DIPHOSPHONATES; DISEASE; ESTROGEN REPLACEMENT THERAPY; FEMALE; FRACTURES, SPONTANEOUS; HUMANS; OSTEOPOROSIS; OVULATION; PREMENOPAUSE; RISK FACTORS;

EID: 24344446905     PISSN: 17012163     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1701-2163(16)30461-3     Document Type: Article

References (23)

1. Khan AA, Bachrach L, Brown JP, Hanley DA, Josse RG, Kendler DL Standards and guidelines for performing central dual-energy X-ray absorptiometry in premenopausal women, men, and children. J Clin Densitom 2004, 7:51-63.
2. Kanis JA, Melton LJ, Christiansen C, Johnston CC, Khaltaev N The diagnosis of osteoporosis. J Bone Miner Res 1994, 9:1137-1141.
3. Gullberg B, Johnell O, Kanis JA World-wide projections for hip fracture. Osteoporos Int 1997, 7:407-413.
4. Hui SL, Slemenda CW, Johnston CC Age and bone mass as predictors of fracture in a prospective study. J Clin Invest 1988, 81:1804-1809.
5. Sowers M, Kshirsagar A, Crutchfield M, Updike S Body composition, age and femoral bone mass of young adult women. Ann Epidemiol 1991, 1:245-254.
6. Hosmer WD, Genant HK, Browner WS Fractures before menopause: a red flag for physicians. Osteoporos Int 2002, 13:337-341.
7. Khan AA, Syed Z Bone densitometry in premenopausal women. J Clin Densitom 2004, 7(1):85-92.
8. Prior JC, Vigna YM, Schechter MT, Burgess AE. Spinal bone loss and ovulatory disturbances. N Engl J Med 19901;323:1221-7.
9. Sowers M, Randolph JF, Crutchfield M, Jannausch ML, Shapiro B, Zhang B, et al. Urinary ovarian and gonadotropin hormone levels in premenopausal women with low bone mass. J Bone Miner Res 1998, 1998(13):1191-1202.
10. Sowers M, Crutchfield M, Bandekar R, Randolph JF, Shapiro B, Schork MA, et al. Bone mineral density and its change in pre-and perimenopausal white women: the Michigan Bone Health Study. J Bone Miner Res 1998, 13:1134-1140.
11. Sowers M, Clark MK, Hollis B, Wallace RB, Jannausch M Radial bone mineral density in pre- and perimenopausal women: a prospective study of rates and risk factors of loss. J Bone Miner Res 1992, 7:647-657.
12. Warming L, Hassager C, Christiansen C Changes in bone mineral density with age in men and women: a longitudinal study. Osteoporos Int 2002, 13:105-112.
13. Khan AA, Bilezikian JP, Kung AW, Ahmed MM, Dubois SJ, Ho AY, et al. Alendronate in primary hyperparathyroidism: a double-blind, randomized, placebo-controlled trial. J Clin Endocrinol Metab 2004, 89:3319-3325.
14. Brown JP, Josse RG Clinical practice guidelines for the diagnosis and management of osteoporosis in Canada. Can Med Assoc J 2002, 167(10):S1-S35.
15. Goldsmith NF, Johnston JO Bone mineral: effects of oral contraceptives, pregnancy, and lactation. J Bone Joint Surg 1975, 57:657-668.
16. Prior JC, Vigna YM, Barr SI, Rexworth C, Lentle BC Cylic medroxyprogesterone treatment increases bone density: a controlled trial in active women with menstrual cycle disturbances. Am J Med 1994, 96:521-530.
17. DeCherney A. Bone-sparing properties of oral contraceptives. Am J Obstet Gynecol 1996, 174:15-20.
18. Ott SM, Scholes D, LaCroix AZ, Ichikawa LE, Yoshida CK, Barlow WE Effects of contraceptive use on bone biochemical markers in young women. J Clin Endocrinol Metab 2001, 86:179-185.
19. Prior JC, Kirkland SA, Joseph L, Kreiger N, Murray TM, Hanley DA, et al. Oral contraceptive use and bone mineral density in premenopausal women: cross-sectional, population based data from the Canadian Multicentre Osteoporosis Study. CMAJ 2001, 165(8):1023-1029.
20. Fraser IS, Weisberg E A comprehensive review of injectable contraception with special emphasis on depot medroxyprogesterone acetate. Med J Aust 1981, 24(Suppl 1):3-19.
21. Jeppsson S, Johansson EDB Medroxyprogesterone acetate, estradiol, FSH, and LH in peripheral blood after intramuscular administration of Depo-Provera ® to women. Contraception 1976, 14:461-469.
22. Paiva LC, Pinto-Neto AM, Faundes A Bone density among long-term users of medroxyprogesterone acetate as a contraceptive. Contraception 1988, 58:351-355.
23. Wanichsetakul P, Kamudhamas A, Watanaruagniobit P, Siripakarn Y, Visutakul P Bone mineral density at various anatomic bone sites in women receiving oral contraceptives and depot-medroxyprogesterone acetate for contraception. Contraception 2002, 65(6):407-510.